title: Clevidipine (the Medicines Company).
abstract: The Medicines Company (under license from AstraZeneca) is developing clevidipine, a short-acting dihydropyridine calcium antagonist, for the potential treatment of peri-operative hypertension. By 1997, the compound was undergoing phase II clinical evaluation by the original developer, AstraZeneca. By March 2002, The Medicines Company was conducting phase III clinical trials.
authors.affiliation: Department of General Surgery, The Second Affiliated Hospital of Zhong Shan University, Guangzhou, PR China. hongweizhang67@hotmail.com
authors.forename: Hongwei
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D006801:Humans; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D011725:Pyridines; C118563:clevidipine